FUCHS JAMES J 4
4 · PRAXAIR INC · Filed Nov 12, 2009
Insider Transaction Report
Form 4
FUCHS JAMES J
Senior Vice President
Transactions
- Sale
Common Stock
2009-11-11$82.78/sh−9,000$744,989→ 6,394 total(indirect: By Spouse)
Holdings
- 809.883(indirect: By 401(k))
Common Stock
- 69,400
Stock Option (right to buy)
Exercise: $61.47From: 2008-02-27Exp: 2017-02-27→ Common Stock (69,400 underlying) - 1,100.317
Deferred Stock
Exercise: $0.00→ Common Stock (1,100.317 underlying) - 62,600
Stock Option (right to buy)
Exercise: $53.98From: 2007-02-28Exp: 2016-02-28→ Common Stock (62,600 underlying) - 22,000
Stock Option (right to buy)
Exercise: $83.89From: 2011-02-26Exp: 2018-02-26→ Common Stock (22,000 underlying) - 59,560
Stock Option (right to buy)
Exercise: $60.92From: 2010-02-24Exp: 2019-02-24→ Common Stock (59,560 underlying) - 4,486
Common Stock
- 40,000
Stock Option (right to buy)
Exercise: $83.89From: 2009-02-26Exp: 2018-02-26→ Common Stock (40,000 underlying)
Footnotes (5)
- [F1]The $82.7765 price reported is the weighted average sale price. The sale prices ranged from $82.7507 to $82.804 per share. Upon request of the SEC Staff, Praxair, Inc. or a security holder of Praxair, Inc., the reporting person will provide full information regarding the number of shares sold at each separate price.
- [F2]This option became exercisable in three (3) equal annual installments beginning on the first anniversary of the date of grant.
- [F3]This option will vest in full if Praxair, Inc. achieves cumulative fiscal year earnings per share growth of at least 33% over 2007 earnings per share at any time prior to January 1, 2011. If vested, the option may be exercised beginning on the third anniversary of the grant date. If Praxair, Inc. fails to meet the cumulative earnings per share goal, this option will be forfeited.
- [F4]This option vests over three years in three consecutive equal annual installments beginning on February 24, 2010.
- [F5]Deferred stock units acquired under the Praxair, Inc. Compensation Deferral Program as amended ("Deferred Program") and are to be settled in Praxair Common Stock.